Entry
Name
Endometrial cancer
Description
Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.
Class
Human Diseases; Cancer: specific types
BRITE hierarchy
Pathway map
Ortholog table
Disease
Orthology
K04357 epidermal growth factor
K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta [EC:2.7.1.153 ]
K02649 phosphoinositide-3-kinase regulatory subunit alpha/beta/delta
K02158 Bcl-2-antagonist of cell death
K09408 forkhead box protein O3
K04364 growth factor receptor-bound protein 2
K08845 A-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K04365 B-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K04366 RAF proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K04375 ETS domain-containing protein Elk-1
K08734 DNA mismatch repair protein MLH1
K05689 cadherin 1, type 1, E-cadherin
K02085 adenomatosis polyposis coli protein
K04490 transcription factor 7-like 1
K04491 transcription factor 7-like 2
K04492 lymphoid enhancer-binding factor 1
K04377 Myc proto-oncogene protein
K04503 G1/S-specific cyclin-D1
K06625 cyclin-dependent kinase inhibitor 1A
K04402 growth arrest and DNA-damage-inducible protein
K02159 apoptosis regulator BAX
K14021 Bcl-2 homologous antagonist/killer
K10140 DNA damage-binding protein 2
Compound
C05981 Phosphatidylinositol-3,4,5-trisphosphate
Reference
Authors
Ryan AJ, Susil B, Jobling TW, Oehler MK.
Title
Endometrial cancer.
Journal
Reference
Authors
Lax SF.
Title
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
Journal
Reference
Authors
Shiozawa T, Konishi I.
Title
Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.
Journal
Reference
Authors
Hecht JL, Mutter GL.
Title
Molecular and pathologic aspects of endometrial carcinogenesis.
Journal
Reference
Authors
Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.
Title
Molecular pathology of endometrial hyperplasia and carcinoma.
Journal
Reference
Authors
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.
Title
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Journal
Reference
Authors
Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
Title
Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Journal
Cancer Res 55:5693-8 (1995)
Reference
Authors
Kim D, Chung J.
Title
Akt: versatile mediator of cell survival and beyond.
Journal
Related pathway
ko04060 Cytokine-cytokine receptor interaction
LinkDB
All DBs